Screening tool does not improve cancer patient mood states

This article originally appeared here.
Screening Tool Does Not Cut Distress in Cancer Patients
Screening Tool Does Not Cut Distress in Cancer Patients

(HealthDay News) -- Distress monitoring and needs assessment using the Distress Thermometer and Problem List (DT&PL) does not appear to be cost-effective in improving mood states in cancer patients, according to research published online Sept. 3 in the Journal of Clinical Oncology.

William Hollingworth, Ph.D., of the University of Bristol in the United Kingdom, and colleagues randomly assigned 220 cancer patients starting radiotherapy or chemotherapy to an intervention group (112 patients) or a control group (108 patients). The effect of a 25-minute intervention with the DT&PL on patient outcomes and health care costs was assessed.

The researchers found that, among the patients receiving the intervention, one-third reported high levels of distress; most patients reported physical (84 percent) or emotional (56 percent) problems. No evidence of an effect of the DT&PL was observed for psychological distress, quality of life, or health care costs. Fewer than 3 percent of patients in either group were referred to a clinical psychologist.

"Needs can be identified using short, simple, and inexpensive screening tools," writes the author of an accompanying editorial. "However, results need to be followed-up with further assessment of specific needs and appropriate referral and treatment."

Full Text (subscription or payment may be required)

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs